What should I do if I become resistant to Sarilumab?

Interleukin-6 receptor inhibitor Sarilumab (Sarilumab) Compared with traditional disease-modifying synthetic antirheumatic drugs(csDM It has shown efficacy in combination with ARDs) or as monotherapy in patients with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response (IR) or intolerance (INT) to methotrexate (MTX) or tumor necrosis factor (TNF)-alpha inhibitors.

In phase III clinical trials, salirumab has been shown to be effective in patients with IR or patients sensitive to csDMARDs (including MTX) and tumor necrosis factor (TNF)-alpha inhibitors, and has been shown to be superior to adalimumab monotherapy in improving RA signs and symptoms and physical function in patients with IR or patients sensitive to MTX. The most common side effects of Salirumab are neutropenia, increased levels of a liver enzyme called ALT in the blood, reddening of the skin at the injection site, nose and throat infections, and infections of the structures that carry urine (such as the bladder). However, everyone has a different body constitution and a different drug resistance response. If you feel unwell, please inform your doctor in time.

The patent drug Thalilutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. The common dosage form of Salirutumab's original drug is injection, which has been marketed overseas. The price of the European version of the specification200mg*2 per box is around 17,500 (the price may fluctuate due to the exchange rate). There are currently no generic Salirutumab produced in other countries.